Feed VIRP.PA
VI

Virbac SA

VIRP.PA · PAR

310.50 € +0.98% (+3.00 €)
1M -4.65%
Market Cap 2.60B €
P/E Ratio 17.24x
Div. Yield 0.47%
ROE 13.56%

Bulios Fair Price

390.55 €

25.8% upside

Current Price

310.5 €

Undervalued Fair Value Overvalued

According to Bulios Fair Price, VIRP.PA is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Moderate
5/9
Valuation
63 /100
Fair
EV/EBITDA 9.98x
P/S 1.78x
P/B 2.31x
Growth
67 /100
Growing
Rev. growth 6.39%
FCF growth 31.57%
Book val. growth 10.26%
Profitability
61 /100
Moderate
Net margin 10.30%
Op. margin 14.89%
FCF margin 7.06%
Quality
62 /100
Average
ROE 13.56%
ROA 7.88%
Asset turnover 0.77x
Debt
96 /100
Low
Current ratio 1.53x
Int. coverage 25.29x
Net debt/EBITDA 0.62x
Stability
100 /100
Stable
Rev. volatility 4.98%
EPS volatility 11.10%
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about VIRP.PA
Online

About the company

Virbac SA is a French pharmaceutical company specializing in the development, manufacturing, and distribution of veterinary medicines. Founded in 1968 and headquartered in Carros, France, Virbac is known for its wide range of products for animals, including medications, vaccines, and diagnostic tools aimed at improving animal health and preventing diseases. The company operates globally, and its products are designed for both pets and livestock.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Paul Martingell

Employees

6,442

Headquarters

Carros

Upcoming events

23 MAR

Earnings

Upcoming earnings report

174d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.